BRPI0713402A2 - use of thymosin alfa 1 to prepare a drug for the treatment of stage iv melanoma melanoma - Google Patents
use of thymosin alfa 1 to prepare a drug for the treatment of stage iv melanoma melanoma Download PDFInfo
- Publication number
- BRPI0713402A2 BRPI0713402A2 BRPI0713402-9A BRPI0713402A BRPI0713402A2 BR PI0713402 A2 BRPI0713402 A2 BR PI0713402A2 BR PI0713402 A BRPI0713402 A BR PI0713402A BR PI0713402 A2 BRPI0713402 A2 BR PI0713402A2
- Authority
- BR
- Brazil
- Prior art keywords
- melanoma
- prepare
- stage
- treatment
- drug
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title abstract 4
- 102000007501 Thymosin Human genes 0.000 title abstract 2
- 108010046075 Thymosin Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DA TIMOSINA ALFA 1 PARA PREPARAR UM MEDICAMENTO PARA O TRATAMENTO DO MELANOMA MALIGNO EM ESTáGIO IV. A presente invenção refere-se ao uso da timosina alfa em combinação com a dacarbazina e opcionalmente com Interferona alfa para preparar um medicamento para o tratamento do melanoma maligno no estágio IV, caracterizado por metástase distante não-operável.USE OF ALPHA 1 TIMOSINE TO PREPARE A MEDICINAL PRODUCT FOR TREATMENT OF MALIGNO MELANOMA IN STAGE IV. The present invention relates to the use of thymosin alfa in combination with dacarbazine and optionally interferon alfa to prepare a medicament for the treatment of stage IV malignant melanoma characterized by distant non-operable metastasis.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/424,425 US7481633B2 (en) | 2006-06-15 | 2006-06-15 | Rotor with cut-outs |
| US11/424,425 | 2006-06-15 | ||
| US11/734,592 US8017129B2 (en) | 2006-06-15 | 2007-04-12 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
| US11/734,592 | 2007-04-12 | ||
| PCT/EP2007/053712 WO2007144218A1 (en) | 2006-06-15 | 2007-04-17 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0713402A2 true BRPI0713402A2 (en) | 2012-03-13 |
Family
ID=45809859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0713402-9A BRPI0713402A2 (en) | 2006-06-15 | 2007-04-17 | use of thymosin alfa 1 to prepare a drug for the treatment of stage iv melanoma melanoma |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRPI0713402A2 (en) |
-
2007
- 2007-04-17 BR BRPI0713402-9A patent/BRPI0713402A2/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201903693T4 (en) | dosing and drive mechanism for the drug delivery device. | |
| PL1986669T3 (en) | The use of Bifidobacterium longum for the prevention and treatment of inflammation | |
| GEP20135902B (en) | Injection syringe for therapeutic agent | |
| UA105210C2 (en) | Anti-cancer vaccine and use thereof | |
| BRPI0719009B8 (en) | dosing and triggering mechanism for drug delivery devices | |
| ATE493161T1 (en) | MEDICAL DELIVERY SYSTEM WITH ASYMMETRIC CODING DEVICES | |
| UY27720A1 (en) | MONOCYCLIC AROILPIRIDINONES, | |
| EA200802247A1 (en) | DOSING SCHEME OF KLADRIBIN FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| MY173629A (en) | Dosage form | |
| BRPI0717369A2 (en) | COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND. | |
| DE60327693D1 (en) | TOPICAL COMPOSITION CONTAINING A CYCLOFRUCTAN, A CARRIER AND A MEDICAMENT | |
| TW200800954A (en) | Novel crystal modifications | |
| BRPI0516577A (en) | therapeutic agents with reduced toxicity | |
| CL2009000665A1 (en) | Pyrrolidinyl derived compounds; pharmaceutical composition comprising said compounds; and its use in the treatment of anxiety, depression or both. | |
| CL2009001841A1 (en) | Use of a sustained release composition of 4-aminopyridine to prepare a medicament useful for treating multiple sclerosis in a subject. | |
| ECSP11011101A (en) | CYCLOUNDECADEPSIPEPTIDE COMPOUNDS AND THE USE OF SUCH COMPOUNDS AS A MEDICINAL PRODUCT | |
| SG160415A1 (en) | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | |
| AR061352A1 (en) | THE USE OF TIMOSINA ALFA 1 TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF MALIGNOM MELANOMA OF STADIUM IV | |
| NO20091628L (en) | combination Drug | |
| TW200642682A (en) | A combination of medical drugs to augment the anti-cancer effect of chemotherapy | |
| BRPI0514753A (en) | pharmaceutical dosage forms comprising a low solubility drug and a polymer | |
| BRPI0518855A2 (en) | medicine for hygienic application to the ear | |
| BRPI0507463A (en) | use of glufosfamide and gemcitabine, product, and, combination of glufosfamide and gemcitabine | |
| BRPI0713402A2 (en) | use of thymosin alfa 1 to prepare a drug for the treatment of stage iv melanoma melanoma | |
| GEP20115158B (en) | Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |